Semaglutide: Brands, Uses and Treatment

Each indication has eligibility requirements. For example, Wegovy's cardiovascular indication requires established cardiovascular disease and overweight or obesity. Its liver indication is for a specified stage of metabolic dysfunction-associated steatohepatitis, or MASH, and received accelerated approval subject to confirmatory evidence.

Current options have expanded beyond the original weekly injection. The prescription should identify the exact product. A tablet dose cannot be converted to an injection dose by comparing milligrams, and Rybelsus and Ozempic tablets are explicitly not substitutable milligram for milligram.

Semaglutide increases insulin release and reduces glucagon release when glucose is elevated. It influences appetite and delays stomach emptying. That can reduce hunger and the amount eaten, while helping control blood sugar in diabetes. Response is assessed over time as the dose is adjusted.

Low starting doses are used to reduce digestive effects. The prescribed schedule depends on the formulation and reason for treatment. Oral products require an empty stomach, a limited amount of water, and a wait before food, drinks, or other oral medicines. Weekly injections have different administration and missed-dose instructions.

Semaglutide products are contraindicated with a personal or family history of medullary thyroid carcinoma, MEN2, or serious hypersensitivity to the product. The boxed thyroid warning reflects animal findings; whether semaglutide causes these tumors in humans is unknown. Ordinary thyroid problems require assessment but are a different diagnosis.

Discuss pancreatitis, gallbladder disease, severe gastroparesis, kidney problems, diabetic retinopathy, and other medicines. Insulin or sulfonylurea doses may need adjustment. Tell the clinician about pregnancy plans: semaglutide should be stopped at least two months before a planned pregnancy. Treatment during pregnancy depends on the indication and requires specific medical advice.

An approved brand and a compounded semaglutide preparation have different regulatory status. FDA does not review compounded products for safety, effectiveness, and quality before marketing. Semaglutide sodium and acetate are different active ingredients from the semaglutide used in approved medicines, and FDA warns against their use in compounding.

For any prescription, verify the pharmacy, formulation, labeled strength, and administration training. Report persistent vomiting, severe abdominal pain, dehydration, or allergic symptoms promptly. Keep follow-up in place for benefit, nutrition, side effects, and the condition being treated.